Cargando…
Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19
Fluvoxamine is a well-tolerated, widely available, inexpensive selective serotonin reuptake inhibitor that has been shown in a small, double-blind, placebo-controlled, randomized study to prevent clinical deterioration of patients with mild coronavirus disease 2019 (COVID-19). Fluvoxamine is also an...
Autores principales: | Sukhatme, Vikas P., Reiersen, Angela M., Vayttaden, Sharat J., Sukhatme, Vidula V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094534/ https://www.ncbi.nlm.nih.gov/pubmed/33959018 http://dx.doi.org/10.3389/fphar.2021.652688 |
Ejemplares similares
-
Fluvoxamine for the treatment of COVID-19
por: Dodds, Michael G, et al.
Publicado: (2022) -
Repurposing Drugs in Oncology (ReDO)—mebendazole as an anti-cancer agent
por: Pantziarka, Pan, et al.
Publicado: (2014) -
Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent
por: Pantziarka, Pan, et al.
Publicado: (2015) -
Repurposing Drugs in Oncology (ReDO)—diclofenac as an anti-cancer agent
por: Pantziarka, Pan, et al.
Publicado: (2016) -
Repurposing drugs in oncology (ReDO)—cimetidine as an anti-cancer agent
por: Pantziarka, Pan, et al.
Publicado: (2014)